Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized placebo-controlled study of cilofexor in non-cirrhotic primary sclerosing cholangitis
MOH_2019-08-06_007323Phase 3Completed
- Sponsor
- Madrigal Pharmaceuticals
- Start
- Jun 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of cilofexor in Primary Sclerosing Cholangitis (PSC) (3 arms), sponsored by Madrigal Pharmaceuticals. Started Jun 2019; status: completed.
02
Drugs
cilofexor
03
Conditions
Primary Sclerosing Cholangitis (PSC)
Beyond the preview
Go deeper on MOH_2019-08-06_007323.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2019-08-06_007323.